FDA approves new anesthetic/sedation drug option
The Food and Drug Administration yesterday approved a new drug application for , an intravenous general anesthetic and sedation drug in short supply.
鈥淭he agency recognizes there is increased demand for certain products, such as propofol injectable emulsion, during the novel coronavirus pandemic, and remains committed to facilitating access to safe and effective medical products to help address critical needs of the American public,鈥 the agency .
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna鈥檚 Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that鈥
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention鈥
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition鈥
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-鈥
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been鈥